ReviewJournal of immunology research2016
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.
Review in Journal of immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Research progress and challenges of the PD-1/PD-L1 axis in gliomas.Cell & bioscience · 2024Review
- Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2023Review
- Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma.Science translational medicine · 2023Article
- ROS regulation in gliomas: implications for treatment strategies.Frontiers in immunology · 2023Review
- Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature.Journal of Cancer · 2023Article
- Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2022Review
- Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.Journal of experimental & clinical cancer research : CR · 2022Review
- Impact of human papillomavirus on the tumor microenvironment in oropharyngeal squamous cell carcinoma.International journal of cancer · 2022Article
- Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Glioblastoma Multiforme-A Look at the Past and a Glance at the Future.Pharmaceutics · 2021Review
- Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).International journal of molecular medicine · 2021Review
- Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?International journal of molecular sciences · 2020Review
- Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.Cellular and molecular life sciences : CMLS · 2020Review
- Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.Therapeutic advances in gastroenterology · 2020Review
- A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.International journal of cancer · 2019Article
- A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling.Oncotarget · 2019Article
- From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions.Frontiers in oncology · 2019Review
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.Neurologia medico-chirurgica · 2018Review
- Immune checkpoint receptors: homeostatic regulators of immunity.Hepatology international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.